Literature DB >> 18580679

Expression of the interferon regulatory factor 8/ICSBP-1 in human reactive lymphoid tissues and B-cell lymphomas: a novel germinal center marker.

Antonio Martinez1, Stefania Pittaluga, Martina Rudelius, Theresa Davies-Hill, Denise Sebasigari, Thomas J Fountaine, Stephen Hewitt, Elaine S Jaffe, Mark Raffeld.   

Abstract

To assess the role of interferon regulatory factor (IRF) 8 in B-cell development and lymphomagenesis, we studied its expression in reactive lymphoid tissues, its relationship to other B-cell transcription factors, and its expression in a series of 232 B-cell tumors and 30 cell lines representing a variety of B-cell developmental stages. We found that although IRF8 was detectable in most reactive B-cells, its expression levels differed with developmental stage. Germinal center B cells contained the highest levels of IRF8, with lower levels seen in mantle and marginal zone B cells and none in plasma cells. IRF8 was coexpressed with PAX-5, Pu.1, and B-cell lymphoma (BCL)-6, and similar to BCL-6, was absent from the small population of IRF4-positive germinal center B cells thought to be committed to postgerminal center developmental programs. Similarly, IRF8 was most strongly expressed in lymphomas of germinal center origin with lower levels present in mantle cell lymphomas, chronic lymphocytic leukemia, and marginal zone lymphomas, and no expression observed in plasmacytic/plasmablastic neoplasms. The reciprocal expression pattern with IRF4 in reactive tissues was generally maintained in lymphomas with some exceptions. These results suggest an important role for IRF8 during germinal center B-cell development and in related lymphomas, and provide a new diagnostic marker helpful in distinguishing B-cell non-Hodgkin lymphoma subtypes.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18580679      PMCID: PMC9036392          DOI: 10.1097/PAS.0b013e318166f46a

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  36 in total

1.  BCL-6, a POZ/zinc-finger protein, is a sequence-specific transcriptional repressor.

Authors:  C C Chang; B H Ye; R S Chaganti; R Dalla-Favera
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-09       Impact factor: 11.205

Review 2.  The role of IRF-4 in B and T cell activation and differentiation.

Authors:  Alessandra B Pernis
Journal:  J Interferon Cytokine Res       Date:  2002-01       Impact factor: 2.607

Review 3.  ICSBP/IRF-8 transactivation: a tale of protein-protein interaction.

Authors:  Ben-Zion Levi; Sharon Hashmueli; Merav Gleit-Kielmanowicz; Aviva Azriel; David Meraro
Journal:  J Interferon Cytokine Res       Date:  2002-01       Impact factor: 2.607

Review 4.  Regulation of lymphocyte cell fate decisions and lymphomagenesis by BCL-6.

Authors:  L M Staudt; A L Dent; A L Shaffer; X Yu
Journal:  Int Rev Immunol       Date:  1999       Impact factor: 5.311

5.  Transcriptional repression of Stat6-dependent interleukin-4-induced genes by BCL-6: specific regulation of iepsilon transcription and immunoglobulin E switching.

Authors:  M B Harris; C C Chang; M T Berton; N N Danial; J Zhang; D Kuehner; B H Ye; M Kvatyuk; P P Pandolfi; G Cattoretti; R Dalla-Favera; P B Rothman
Journal:  Mol Cell Biol       Date:  1999-10       Impact factor: 4.272

6.  Requirement for the transcription factor LSIRF/IRF4 for mature B and T lymphocyte function.

Authors:  H W Mittrücker; T Matsuyama; A Grossman; T M Kündig; J Potter; A Shahinian; A Wakeham; B Patterson; P S Ohashi; T W Mak
Journal:  Science       Date:  1997-01-24       Impact factor: 47.728

7.  PU.1 protein expression has a positive linear association with protein expression of germinal centre B cell genes including BCL-6, CD10, CD20 and CD22: identification of PU.1 putative binding sites in the BCL-6 promotor.

Authors:  Emina Torlakovic; Agnieszka Malecka; June H Myklebust; Anne Tierens; Hans-Christian Aasheim; Jahn M Nesland; Erlend Smeland; Stein Kvaløy; Jan Delabie
Journal:  J Pathol       Date:  2005-07       Impact factor: 7.996

8.  Stages of germinal center transit are defined by B cell transcription factor coexpression and relative abundance.

Authors:  Giorgio Cattoretti; Rita Shaknovich; Paula M Smith; Hans-Martin Jäck; Vundavalli V Murty; Bachir Alobeid
Journal:  J Immunol       Date:  2006-11-15       Impact factor: 5.422

9.  Direct repression of prdm1 by Bcl-6 inhibits plasmacytic differentiation.

Authors:  Chainarong Tunyaplin; A L Shaffer; Cristina D Angelin-Duclos; Xin Yu; Louis M Staudt; Kathryn L Calame
Journal:  J Immunol       Date:  2004-07-15       Impact factor: 5.422

10.  ICSBP is critically involved in the normal development and trafficking of Langerhans cells and dermal dendritic cells.

Authors:  Giovanna Schiavoni; Fabrizio Mattei; Paola Borghi; Paola Sestili; Massimo Venditti; Herbert C Morse; Filippo Belardelli; Lucia Gabriele
Journal:  Blood       Date:  2003-11-13       Impact factor: 22.113

View more
  23 in total

Review 1.  IRF8 regulates myeloid and B lymphoid lineage diversification.

Authors:  Hongsheng Wang; Herbert C Morse
Journal:  Immunol Res       Date:  2009       Impact factor: 2.829

2.  A reporter mouse reveals lineage-specific and heterogeneous expression of IRF8 during lymphoid and myeloid cell differentiation.

Authors:  Hongsheng Wang; Ming Yan; Jiafang Sun; Shweta Jain; Ryusuke Yoshimi; Sanaz Momben Abolfath; Keiko Ozato; William G Coleman; Ashley P Ng; Donald Metcalf; Ladina DiRago; Stephen L Nutt; Herbert C Morse
Journal:  J Immunol       Date:  2014-07-14       Impact factor: 5.422

Review 3.  The follicular lymphoma microenvironment: From tumor cell to host immunity.

Authors:  Antonio Martinez; Joaquim Carreras; Elias Campo
Journal:  Curr Hematol Malig Rep       Date:  2008-10       Impact factor: 3.952

4.  Interferon regulatory factor 8 (IRF8) interacts with the B cell lymphoma 6 (BCL6) corepressor BCOR.

Authors:  Jeongheon Yoon; Xianxum Feng; Yong-Soo Kim; Dong-Mi Shin; Katerina Hatzi; Hongsheng Wang; Herbert C Morse
Journal:  J Biol Chem       Date:  2014-10-20       Impact factor: 5.157

5.  Differential expression of IRF8 in subsets of macrophages and dendritic cells and effects of IRF8 deficiency on splenic B cell and macrophage compartments.

Authors:  Chen-Feng Qi; Zhaoyang Li; Mark Raffeld; Hongsheng Wang; Alexander L Kovalchuk; Herbert C Morse
Journal:  Immunol Res       Date:  2009       Impact factor: 2.829

Review 6.  New insights into the regulation of human B-cell differentiation.

Authors:  Heike Schmidlin; Sean A Diehl; Bianca Blom
Journal:  Trends Immunol       Date:  2009-05-15       Impact factor: 16.687

7.  New developments in the pathology of malignant lymphoma: a review of the literature published from May to July 2008.

Authors:  J Han van Krieken
Journal:  J Hematop       Date:  2008-09       Impact factor: 0.196

8.  Activation of the endoplasmic reticulum stress-associated transcription factor x box-binding protein-1 occurs in a subset of normal germinal-center B cells and in aggressive B-cell lymphomas with prognostic implications.

Authors:  Olga Balague; Ana Mozos; Daniel Martinez; Luis Hernandez; Lluis Colomo; Jose Luis Mate; Julie Teruya-Feldstein; Oscar Lin; Elias Campo; Armando Lopez-Guillermo; Antonio Martinez
Journal:  Am J Pathol       Date:  2009-04-23       Impact factor: 4.307

9.  A capture-sequencing strategy identifies IRF8, EBF1, and APRIL as novel IGH fusion partners in B-cell lymphoma.

Authors:  Hakim Bouamar; Saman Abbas; An-Ping Lin; Long Wang; Daifeng Jiang; Kenneth N Holder; Marsha C Kinney; Scott Hunicke-Smith; Ricardo C T Aguiar
Journal:  Blood       Date:  2013-06-17       Impact factor: 22.113

Review 10.  B cells gone rogue: the intersection of diffuse large B cell lymphoma and autoimmune disease.

Authors:  Jean L Koff; Christopher R Flowers
Journal:  Expert Rev Hematol       Date:  2016-05-13       Impact factor: 2.929

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.